Changing Standard of Care: Potential of Tarlatamab in SCLC Treatment

Author(s):

Panelists discuss how the DeLLphi-301 clinical trial demonstrates an objective response rate of 32% to 40% with tarlatamab, which is clinically meaningful given the rapid onset of responses observed between 5 and 7 weeks, while also considering the implications of a median overall survival of 14 months and the duration of response exceeding 6six months for relapsed or refractory extensive-stage small cell lung cancer.

EP: 1.Current Landscape of First-Line Treatment for Limited-Stage SCLC: Diagnostic Workup & Multidisciplinary Approaches

EP: 2.Surgical and Radiotherapy Choices in Limited-Stage SCLC

EP: 3.Durvalumab in LS-SCLC: Exploring Phase 3 ADRIATIC Trial Outcomes and Implications

EP: 4.Immunotherapy in Limited-Stage SCLC

EP: 5.Defining Platinum Sensitivity in SCLC

Now Viewing

EP: 6.Changing Standard of Care: Potential of Tarlatamab in SCLC Treatment

EP: 7.Adverse Event Management: CRS and ICANS with Tarlatamab

EP: 8.Tarlatamab in Combination Therapy: Future Potential for SCLC

EP: 9.Ifinatamab Deruxtecan and B7-H3 in SCLC

EP: 10.Comparing Treatment Schedules: Ifinatamab Deruxtecan vs Amrubicin, Topotecan, and Lurbinectedin in SCLC

EP: 11.Insights from ARTEMIS-001

EP: 12.Targeted Therapies and Biomarkers for SCLC: What’s Next on the Horizon

Video content above is prompted by the following:

3. Dr Leal: Please share your insights on an objective response rate (ORR) range of 32% to 40% among participants in the 10-mg and 100-mg groups of the DeLLPhi-301 clinical trial.

How clinically meaningful is an objective response observed between 5 and 7 weeks of tarlatamab initiation?
Please express your views on selecting ORR as the primary end point in this study.

Changing standard of care with tarlatamab

5. Dr Sen: Despite the relatively small numbers of complete response and partial response responders (n=68) in DeLLphi-301, please discuss your opinion on the duration of response (DOR) to tarlatamab at >6 months (59%); at >9 months (29%); and the ongoing response at data cutoff [>50% (n=38)] in the 2 treatment groups?